Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Cancer Type
3.2. Snippet by Grade
3.3. Snippet by Treatment Type
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Demand for Novel Therapeutics
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. PESTEL Analysis
5.8. Patent Analysis
5.9. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Cancer Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Non-Muscle Invasive Bladder Cancer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Muscle Invasive Bladder Cancer
7.4. Metastatic Bladder Cancer
7.5. Urothelial (Transitional Cell) Bladder Cancer
7.6. Squamous Cell Bladder Cancer
7.7. Papillary Bladder Cancer
7.8. Others
8. By Grade
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Grade
8.1.2. Market Attractiveness Index, By Grade
8.2. Low-Grade Bladder Cancer*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. High-Grade Bladder Cancer
9. By Treatment Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.1.2. Market Attractiveness Index, By Treatment Type
9.2. Chemotherapy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Intravesical Chemotherapy
9.2.3.1. Mitomycin-C
9.2.3.2. Gemcitabine (Gemzar)
9.2.3.3. Docetaxel (Taxotere)
9.2.3.4. Valrubicin (Valstar)
9.2.4. Systemic Chemotherapy
9.2.4.1. Cisplatin and Gemcitabine
9.2.4.2. Carboplatin and Gemcitabine
9.2.4.3. Mvac (Methotrexate (Rheumatrex, Trexall), Vinblastine (Velban), Doxorubicin and Cisplatin)
9.2.4.4. Docetaxel or Paclitaxel
9.2.4.5. Pemetrexed (Alimta)
9.2.4.6. Others
9.3. Radiation Therapy
9.4. Immunotherapy
9.4.1. Local Immunotherapy
9.4.1.1. Bacillus Calmette-Guerin (BCG)
9.4.1.2. Interferon (Roferon-A, Intron A, Alferon)
9.4.2. Systemic Immunotherapy
9.4.2.1. Avelumab (Bavencio)
9.4.2.2. Nivolumab (Opdivo)
9.4.2.3. Pembrolizumab (Keytruda)
9.5. Targeted Therapy
9.5.1. Erdafitinib (Balversa)
9.5.2. Enfortumab Vedotin-Ejfv (Padcev)
9.5.3. Sacituzumab Govitecan (Trodelvy)
9.5.4. Others
9.6. Surgery
9.6.1. Transurethral Bladder Tumor Resection (TURBT)
9.6.2. Radical Cystectomy and Lymph Node Dissection
9.6.3. Others
9.7. Medications
9.8. Gene Therapy
9.9. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Ambulatory Surgical Centers
10.5. Academic and Research Institutes
10.6. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Grade
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Grade
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Grade
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Grade
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Grade
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Johnson & Johnson Services, Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Astellas Pharma Inc.
13.3. Ferring Pharmaceuticals Inc.
13.4. Merck & Co., Inc.
13.5. Genentech, Inc.
13.6. Bristol-Myers Squibb Company
13.7. Pfizer Inc.
13.8. Theralase Technologies Inc.
13.9. Gilead Sciences, Inc.
13.10. ImmunityBio, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us